BIOARCTIC AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 197.5 SEK | +1.96% |
|
+0.41% | -26.25% |
| Apr. 22 | Nordic Stocks Closed Up Monday; Getinge Series B Climbed Highest | DJ |
| Apr. 15 | Nordic Shares Moved Upward Monday; Invisio Led Increases | DJ |
ETFs positioned on BioArctic AB
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.25% | 5 M€ | +8.63% | ||
| 0.89% | 16 M€ | -8.49% | ||
| 0.25% | 148 M€ | +7.01% | - | |
| 0.19% | 2 M€ | -.--% | ||
| 0.07% | 7 M€ | -.--% | - | |
| 0.02% | 773 M€ | -.--% | - | |
| 0.01% | 10 M€ | -3.35% | - | |
| 0.00% | 34 M€ | +2.14% | - |
BioArctic AB is a Sweden-based company engaged in the biotechnology sector. The Company focuses on the research and development of treatments, which aim at diseases that affect the central nervous system (CNS). Its therapeutic areas encompass neurodegenerative disorders, Alzheimer's disease, Parkinson's disease, complete spinal cord injury, as well as other CNS disorders. The Company owns a technology platform, which develops a range of therapeutic monoclonal antibodies. The Company's pipeline includes product candidates in various clinical phases, such as BAN2401, AE1501, BAN0805, imaging and biochemical biomarkers, BBB-technology and SC0806. The Company also operates through SpineMedical AB.
Calendar
2024-05-17
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
197.5
SEK
Average target price
366.2
SEK
Spread / Average Target
+85.42%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -26.25% | 1.59B | |
| +1.51% | 42.75B | |
| +8.57% | 41.34B | |
| +49.22% | 41.61B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- BIOA B Stock
- Funds and ETFs BioArctic AB
